EZN 4176

Drug Profile

EZN 4176

Alternative Names: EZN416; RNA antagonist of the androgen receptor

Latest Information Update: 08 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Santaris Pharma
  • Developer Roche
  • Class Antineoplastics; Oligonucleotides
  • Mechanism of Action Androgen receptor antagonists; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bone cancer; Prostate cancer

Most Recent Events

  • 16 Oct 2014 Discontinued - Preclinical for Bone cancer in USA (IV)
  • 28 Oct 2013 Enzon Pharmaceuticals terminates its licence for EZN 4176
  • 17 Dec 2012 Suspended - Phase-I for Prostate cancer in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top